Alzheimer’s Drug Patent Ruling Affects Amneal’s Exclusivity Suit

• Teva secures win at appeals court in patent litigation battle over generic dementia treatment

• Ruling could affect timing of generic entry, Amneal says in related suit against FDA

ByDana A. Elfin

Allergan Inc. subsidiary Forest Laboratories, the maker of the Alzheimer’s treatment Namenda XR, lost its bid to overturn a district court ruling finding its patents on the drug invalid.

In a nonprecedential Dec. 11 ruling, the U.S. Court of Appeals for the Federal Circuit affirmed a trial court decision in favor of Teva Pharmaceuticals USA Inc. The decision could affect Amneal Pharmaceuticals’ suit against the FDA over exclusivity ...